A similarly designed study in patients with both obesity and diabetes, published in Retina, also linked GLP-1 drugs to lower ...

Top-line results from two large clinical trials by Novo Nordisk, the company behind Ozempic and Wegovy, found oral ...

Novo Nordisk’s stock tumbles after its oral GLP-1 drug didn’t show a statistically significant benefit over a placebo against ...

Adults prescribed a GLP-1 agent had a 12% higher risk for developing a new chronic cough -- one that persists for over 8 ...

The use of weight-loss injections has sky-rocketed, sometimes leading to unique or strange side effects. The most recent ...

Jack Hampton says his wake-up call came on his 40th birthday, when he decided to turn his life around after years of obesity.

Novo Nordisk just announced price cuts for Ozempic and Wegovy, whose list prices as recently as last year were around $1,000 ...

Novo Nordisk was the leader in the space until Eli Lilly launched tirzepatide. The Denmark-based pharmaceutical giant markets ...

A well-planned public health agenda that incorporates GLP-1 drugs has the potential to reduce obesity rates, increase life ...

Medicare is set to reduce prices for 15 high-cost prescription drugs, including popular GLP-1 medications like Ozempic and ...

GLP-1 receptor agonists affect sexual function differently across individuals and influencing libido and hormone levels in ...

The intersection of pharmaceutical and food technologies presents challenges but also opportunities for ingredient suppliers ...